drugset
drugset / Trial / NCT03891615

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

NCT03891615 ↗

Phase 1 Terminated 20 enrolled Massachusetts General Hospital Tesaro, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a combination of drugs as a possible treatment for EGFR-Mutated Advanced Lung Cancer. The names of the study drugs involved in this study are Niraparib and Osimertinib.

Timeline

Start
2019-06-06
Primary completion
2024-07-03
Completion
2024-11-07

Outcome

Outcome not reported

Stopped (Enrollment): “Slow accrual.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Niraparib Small molecule — Oral
Subject Osimertinib Small molecule — Oral

Indications

lung cancer